目的探讨联合检测血清抑制素A(INH-A)、CA125与CA153水平对卵巢癌早期诊断的价值。方法采用全自动化学发光免疫分析法(CLIA)检测卵巢癌组40例，卵巢良性疾病组30例，对照组30名健康女性的血清INH-A、CA125与CA153水平。结果卵巢癌组血清INH-A、CA125与CA153水平明显高于卵巢癌组和卵巢良性疾病组，差异有统计学意义(P＜0.05);三项标志物的阳性率分别为52.5%，60.0%，72.5%，三项联合检测的阳性率为82.5%。卵巢癌组血清INH-A水平高于卵巢良性疾病组和对照组，提示INH-A异常表达可能与卵巢癌的发生密切相关。结论INH-A可能作为诊断卵巢癌的一项肿瘤标志物，联合检测有助于早期诊断卵巢癌以及病情监测。
Objective To explore the early diagnostic values of combined detection of serum INH-A, CA125 and CA153 levels in patients with ovarian carcinoma. Methods The serum levels of INH-A, CA125 and CA153 of 40 patients with ovarian cancer, 30 patients with benign ovarian disease and 30 healthy women controls were measured by CLIA. Results The serum INH-A, CA125 and CA153 levels and positive rate in patients with ovarian cancer were significantly higher than that of in patients with benign ovarian tumor and healthy controls (P＜0. 05). The positive rates of INH-A, CA12 5and CA153 in patients with ovarian cancer were 52.5%,60.0%and 72.5 %, respectively. The positive rate of three markers combined detection was 82.5%. The INH-A levels in patients with ovarian cancer were higher than that in the control group. The abnormal expression of INH-A could be closely related to the occurrence of ovarian cancer, and might be used as a tumor marker for diagnosis of ovarian cancer. Conclusion The joint detection of serum INH-A, CA125, and CA153 levels may be helpful for early diagnosis of ovarian cancer and disease monitoring.
[1] Jobling T,Mamers P, Healy D L, et al.A prospective study of inhibin in granulosa cell tumors of the ovary[J].Gynecol Oncol, 1994, 55(2): 285-289.
[2] Holschneider C H,Berek J S.Ovarian cancer: epidemiology, biology, and prognostic factors[J].Semin Surg Oncol,2000,19(1):3-10.
[3] Kretser D M,Hedger M P,Loveland K L, et al. Inhibins, activins and follistatin in reproduction[J]. Hum Reprod Update, 2002,8(6):529-541.
[4] Knight P G, Glister C. Local roles of TGF-beta superfamily members in the control of ovarian follicle development[J]. Anim Reprod Sci,2003,78(3-4):165-183.
[5] Zheng W, Lu J J, Luo F,et al. Tumor stroma as the main source of inhibin production in ovarian epithelial tumors[J]. Am J Reprod Immunol, 2000, 44(2):104-113.
[6]Fuller P J,Chu S, Jobling T,et al. Inhibin subunit gene expression in ovarian cancers[J]. Gynecol Oncol, 1999, 73(2): 273-279.
[7] Tsigkou A, Marrelli D, Reis F M,et al. Total inhibin is a potential serum marker for epithelial ovarian cancer[J]. J Clin Endocrinol Metab, 2007, 92(7):2526-2531.
[8] 宋一丽,李娜,尹艳英. CA125与抑制素A联合检测在卵巢癌诊断中的临床意义[J].中国妇幼保健, 2011,6(26):821-824.
[9] Meyer T, Rustin G J. Role of tumour markers in monitoring epithelial ovarian cancer[J]. Br J Cancer, 2000,82(9):1535-1538.
[10] 李宜川, 芦琨, 赵炎. 联合检测血清CA125、CA199、CA153和CA742对卵巢癌的诊断价值[J].中国妇幼保健,2012,2(27):271-273.
